Valeo Pharma Enters into a Commercial Services Agreement with Veru for Sabizabulin to Treat COVID-19 in Canada
Shots:
- The P-III trial evaluates sabizabulin (9mg, qd) vs PBO in 204 hospitalized patients with mod. to sev. COVID (≥ WHO 4-supplemental oxygen) who are at high risk for ARDS and death
- The results showed a 55.2% reduction in deaths over PBO & also showed a significant reduction of days in ICU, days on mechanical ventilation, and days in the hospital. The results of the interim analysis from the P-III study were published in The New England Journal of Medicine (NEJM) Evidence
- Veru plans to submit an application to Health Canada requesting that the regulator uses the NDS CV (a prioritized COVID-19 specific review and authorization submission) through ACCESS Consortium regulatory pathway
Ref: PRNewswire | Image: Valeo Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
